Offering's proceeds used for phase 1 clinical development of EPZ-5676
By Devika Patel
Knoxville, Tenn., June 5 - Epizyme, Inc. said the underwriters for its initial public offering of stock opted to exercise the deal's $11.57 million greenshoe in full for total proceeds of $88.7 million. The deal was announced April 18 and priced for $77.13 million with the greenshoe on May 31.
The company sold 5,913,300 common shares at $15.00 apiece. Of the shares, 771,300 were part of the fully exercised greenshoe.
Citigroup, Cowen and Co. and Leerink Swann were the joint bookrunners.
Proceeds will be used for phase 1 clinical development of EPZ-5676, development costs, research and development and working capital and general corporate purposes.
The biopharmaceutical company is based in Cambridge, Mass.
| Issuer: | Epizyme, Inc.
|
| Issue: | Common stock
|
| Amount: | $88,699,500 (including $11,569,500 greenshoe)
|
| Shares: | 5,913,300
|
| Price: | $15.00
|
| Warrants: | No
|
| Bookrunners: | Citigroup, Cowen and Co. and Leerink Swann LLC
|
| Co-managers: | JMP Securities LLC and Wedbush Securities Inc.
|
| Announcement date: | April 18
|
| Pricing date: | May 31
|
| Settlement date: | June 5
|
| Stock exchange: | Nasdaq: EPZM
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
